Literature DB >> 19834972

Fecal calprotectin variability in Crohn's disease.

Bjørn Moum, Jørgen Jahnsen, Tomm Bernklev.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19834972     DOI： 10.1002/ibd.21136

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  18 in total

Review 1.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

2.  Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease.

Authors:  Gilles Boschetti; Marc'harid Laidet; Driffa Moussata; Carmen Stefanescu; Xavier Roblin; Gildas Phelip; Eddy Cotte; Guillaume Passot; Yves Francois; Jocelyne Drai; Emilie Del Tedesco; Yoram Bouhnik; Bernard Flourie; Stephane Nancey
Journal:  Am J Gastroenterol       Date:  2015-03-17       Impact factor: 10.864

3.  Faecal calprotectin for differentiating between irritable bowel syndrome and inflammatory bowel disease: a useful screen in daily gastroenterology practice.

Authors:  Ashwini Banerjee; M Srinivas; Richard Eyre; Robert Ellis; Norman Waugh; K D Bardhan; P Basumani
Journal:  Frontline Gastroenterol       Date:  2014-04-02

4.  Compliance with the faecal calprotectin test in patients with inflammatory bowel disease.

Authors:  Chloé Maréchal; Isabelle Aimone-Gastin; Cédric Baumann; Bastien Dirrenberger; Jean-Louis Guéant; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2017-02-06       Impact factor: 4.623

Review 5.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

Review 6.  The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn's disease.

Authors:  Takayuki Yamamoto
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623

Review 7.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

Review 8.  How to predict clinical relapse in inflammatory bowel disease patients.

Authors:  Elisa Liverani; Eleonora Scaioli; Richard John Digby; Matteo Bellanova; Andrea Belluzzi
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

9.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

10.  Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjögren's syndrome and rheumatoid arthritis.

Authors:  Kristofer Andréasson; Tore Saxne; Agneta Scheja; Izabela Bartosik; Thomas Mandl; Roger Hesselstrand
Journal:  Arthritis Res Ther       Date:  2014-02-06       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.